Search summary:
Session ID: bed2aab740a6b5c1da84208e0e6744bb
Search Type: drug
Started at: 2010-04-14 03:26:18
Finished at: 2010-04-14 03:27:53
| Field | Result | Source |
|---|---|---|
| Name | ||
| candesartan | External | |
| Drugbank ID | ||
| DB00796 | DrugBank | |
| Description | ||
| As all angiotensin II receptor antagonists,and very use full in heart attack candesartan is indicated for the treatment of hypertension. Results from the CHARM study in the early 2000s demonstrated the morbidity and mortality reduction benefits of candesartan therapy in congestive heart failure. Thus, while ACE inhibitors are still considered first-line therapy in heart failure, candesartan can be used in combination with an ACE to achieve improved mortality and morbidity vs. an ACE alone and additionally is an alternative in patients intolerant of ACE inhibitor therapy. | Wikipedia | |
| Candesartan (rINN) (pronounced /ˌkændɨˈsɑrtən/) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. The prodrug candesartan cilexetil is marketed by AstraZeneca and Takeda Pharmaceuticals, commonly under the trade names Blopress, Atacand, Amias, and Ratacand. | Wikipedia | |
| Candesartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Unlike the angiotensin receptor antagonist losartan, Candesartan does not have an active metabolite or possess uricosuric effects. | DrugBank | |
| Chemical Kingdom | ||
| Organic | BioSpider | |
| Chemical Class | ||
| Not Available | Not Applicable | |
| Chemical Species | ||
| alkyl aryl ether | Checkmol | |
| aromatic compound | Checkmol | |
| carboxylic acid | Checkmol | |
| heterocyclic compound | Checkmol | |
| Synonym | ||
| Atacand | DPD | |
| Atacand Tab 16 Mg | DPD | |
| Atacand Tab 8mg | DPD | |
| Blopress | Pubchem | |
| Blopress (TN) | Pubchem | |
| Candesartan (usan/inn) | Pubchem | |
| Candesartan [ban] | Pubchem | |
| Candesartan [usan:inn] | Pubchem | |
| Candesartan cilexetil | Pubchem | |
| UNII-S8Q36MD2XX | Pubchem | |
| Brand Mixture | ||
| Atacand Plus (Candesartan Cilexetil + Hydrochlorothiazide) | DPD | |
| CAS | ||
| 139481-59-7 | DrugBank | |
| InChI Identifier | ||
InChI=1/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-3 3(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25- 12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H 2,1-2H3,(H,35,36,37,38) |
ChemSpider | |
| IUPAC | ||
| 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid | DrugBank | |
| Chemical Formula | ||
| C24H20N6O3 | PubChem | |
| Chemical Structure | ||
 |
Molconvert | |
| Average Molecular Weight (g/mol) | ||
| 440.454000 | BioSpider | |
| Monoisotopic Molecular Weight (g/mol) | ||
| 440.159690 | BioSpider | |
| SMILES (Isomeric) | ||
O=C(OC1CCCCC1)OC(OC(=O)c2cccc3nc(OCC)n(c23)Cc6ccc(c4ccccc4c5nnnn5 )cc6)C |
ChemSpider | |
| SMILES (Canonical) | ||
CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O |
PubChem | |
| Kegg Drug | ||
| D00626 | DrugBank | |
| Kegg Compound | ||
| C07468 | DrugBank | |
| Pubchem Compound ID | ||
| 2541 | DrugBank | |
| Pubchem Substance ID | ||
| 11533318 | Pubchem | |
| 14930481 | Pubchem | |
| 208049 | Pubchem | |
| 29221703 | Pubchem | |
| 46508342 | Pubchem | |
| 4688524 | Pubchem | |
| 48415685 | Pubchem | |
| 49830902 | Pubchem | |
| 49882690 | Pubchem | |
| 50112728 | Pubchem | |
| 53788093 | Pubchem | |
| 56311288 | Pubchem | |
| 56312082 | Pubchem | |
| 56312975 | Pubchem | |
| 56314032 | Pubchem | |
| 56314130 | Pubchem | |
| 57321365 | Pubchem | |
| 75340216 | Pubchem | |
| 7847588 | Pubchem | |
| 80953765 | Pubchem | |
| 81080491 | Pubchem | |
| 8151684 | Pubchem | |
| 85208995 | Pubchem | |
| 85415290 | Pubchem | |
| 91611487 | Pubchem | |
| 9671 | Kegg | |
| OMIM ID | ||
| Not Available | Not Applicable | |
| ChEBI | ||
| 3347 | DrugBank | |
| BioCyc | ||
| Not Available | Not Applicable | |
| PharmGKB | ||
| PA448765 | DrugBank | |
| HET ID | ||
| Not Available | Not Applicable | |
| DPD ID | ||
| 02239090 | DPD | |
| 02239091 | DPD | |
| 02239092 | DPD | |
| 02244021 | DPD | |
| Rxlist Link | ||
| http://www.rxlist.com/cgi/generic/candesar.htm | DrugBank | |
| Wikipedia | ||
| candesartan | Wikipedia | |
| Pdr Health Link | ||
| http://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileName=ata1591.html&contentName=Atacand+HCT&contentId=87 | PDRHealth | |
| Melting Point | ||
| Not Available | Not Applicable | |
| State | ||
| Not Available | Not Applicable | |
| MSDS Link | ||
| Not Available | Not Applicable | |
| FDA Label | ||
| 1271237235.pdf | FDA | |
| Experimental Water Solubility | ||
| Not Available | Not Applicable | |
| Predicted Water Solubility | ||
| 0.00771 mg/mL [Predicted by ALOGPS] | Alogps | |
| Experimental LogP | ||
| Not Available | Not Applicable | |
| Predicted LogP | ||
| 4.02 [Predicted by ALOGPS] | Alogps | |
| pKa | ||
| Not Available | Not Applicable | |
| SDF File | ||
| 1271237193.sdf | Pubchem | |
| Mol File | ||
| 1271237180.mol | Molconvert | |
| Pdb File | ||
| 1271237240.pdb | Molconvert | |
| Mass Spec File | ||
| Not Available | Not Applicable | |
| Associated Disorder | ||
| Not Available | Not Applicable | |
| Pathway | ||
| map07217 - Angiotensin antagonists | Kegg Drug | |
| Category | ||
| Not Available | Not Applicable | |
| ATC Code | ||
| C09CA06 | DPD | |
| AHFS Code | ||
| 24:32.08 | DPD | |
| Schedule | ||
| SCHEDULE F (Canada) | DPD | |
| Indication | ||
| As all angiotensin II receptor antagonists,and very use full in heart attack candesartan is indicated for the treatment of hypertension. Results from the CHARM study in the early 2000s demonstrated the morbidity and mortality reduction benefits of candesartan therapy in congestive heart failure. Thus, while ACE inhibitors are still considered first-line therapy in heart failure, candesartan can be used in combination with an ACE to achieve improved mortality and morbidity vs. an ACE alone and additionally is an alternative in patients intolerant of ACE inhibitor therapy. Prehypertension | Wikipedia | |
| For the treatment of hypertension. | DrugBank | |
| Pharmacology | ||
| Candesartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Unlike the angiotensin receptor antagonist losartan, Candesartan does not have an active metabolite or possess uricosuric effects. | DrugBank | |
| Mechanism Of Action | ||
| ATACAND (candesartan cilexetil), a prodrug, is hydrolyzed to candesartan during absorption from the gastrointestinal tract. Candesartan is a selective AT1 subtype angiotensin II receptor antagonist. | RxList | |
| As all angiotensin II receptor antagonists,and very use full in heart attack candesartan is indicated for the treatment of hypertension. Results from the CHARM study in the early 2000s demonstrated the morbidity and mortality reduction benefits of candesartan therapy in congestive heart failure. Thus, while ACE inhibitors are still considered first-line therapy in heart failure, candesartan can be used in combination with an ACE to achieve improved mortality and morbidity vs. an ACE alone and additionally is an alternative in patients intolerant of ACE inhibitor therapy. Prehypertension | Wikipedia | |
| Candesartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance. | DrugBank | |
| Absorption | ||
| 15% (candesartan cilexetil) | Wikipedia | |
| ATACAND (candesartan cilexetil), a prodrug, is hydrolyzed to candesartan during absorption from the gastrointestinal tract | RxList | |
| Candesartan cilexetil is metabolised completely by esterases in the intestinal wall during absorption to the active candesartan moieity | Wikipedia | |
| Despite this, absolute bioavailability is relatively poor at 15% (candesartan cilexetil tablets) to 40% (candesartan cilexetil solution) | Wikipedia | |
| Following administration of the candesartan cilexetil prodrug, the absolute bioavailability of candesartan was estimated to be 15%. Food with a high fat content has no affect on the bioavailability of candesartan from candesartan cilexetil. | DrugBank | |
| The use of a prodrug form increases the bioavailability of candesartan | Wikipedia | |
| Protein Binding | ||
| Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells. | DrugBank | |
| Half Life | ||
| 5.1–10.5 hours | Wikipedia | |
| Approximately 9 hours. | DrugBank | |
| Biotransformation | ||
| During absorption from the gastrointestinal tract, the prodrug candesartan cilexetil undergoes rapid and complete ester hydrolysis to form the active drug, candesartan. Elimination of candesartan is primarily as unchanged drug in the urine and, by the biliary route, in the feces. Minor hepatic metabolism of candesartan occurs by O-deethylation to form an inactive metabolite. | DrugBank | |
| Toxicity | ||
| No lethality was observed in acute toxicity studies in mice, rats and dogs given single oral doses of up to 2000 mg/kg of candesartan cilexetil or in rats given single oral doses of up to 2000 mg/kg of candesartan cilexetil in combination with 1000 mg/kg of hydrochlorothiazide. In mice given single oral doses of the primary metabolite, candesartan, the minimum lethal dose was greater than 1000 mg/kg but less than 2000 mg/kg. | DrugBank | |
| Results from the CHARM study in the early 2000s demonstrated the morbidity and mortality reduction benefits of candesartan therapy in congestive heart failure. Thus, while ACE inhibitors are still considered first-line therapy in heart failure, candesartan can be used in combination with an ACE to achieve improved mortality and morbidity vs | Wikipedia | |
| Dosage | ||
| Tablet (Oral) | DPD | |
| Patient Information | ||
| 1271237267.html | RxList | |
| Interactions | ||
| Not Available | Not Applicable | |
| Contraindications | ||
| Not Available | Not Applicable | |
| Targets | ||
P30556[ UniProt | Analyze ] |
DrugBank |